Coya Therapeutics, Inc.
NASDAQ:COYABiotechnology
-$0.16 today
- Market cap
- $72.48M
- Beta
- 0.62
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.26
Volume 0.15M
Average 0.16M
COYA Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Coya Therapeutics, Inc.NASDAQ: COYA
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow growth accelerates
Q1 FY2026 free cash flow of $6.21M (cash outflow) rose 119.5% year over year, ahead of the -7.5% change in trailing-twelve-month free cash flow. Sequentially, it rose 516.5% from the prior quarter. Over 3 fiscal years it compounded at +14.0% a year.
Context
- Free cash flow amounted to 135.2% of revenue in FY2025, down 154.3 pp from a year earlier.
- Free cash flow grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +119.5% holds above the trailing-twelve-month pace of -7.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (10.74M) USD
- Year-over-year change
- -4.4%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10.74M) | -4.4% |
| FY2024 | 2024-12-31 | (10.29M) | +8.0% |
| FY2023 | 2023-12-31 | (11.19M) | -54.6% |
| FY2022 | 2022-12-31 | (7.24M) | -79.2% |
| FY2021 | 2021-12-31 | (4.04M) | — |
Free Cash Flow vs competitors
How COYA compares with its peers on the latest reported figures
- COYA's LTM Mar 2026 free cash flow of $14.12M is the 10th largest of the 11 companies compared; the peer median is $41.62M.
- Its year-over-year change of -7.5% is the 6th highest of 11, against a peer median of -10.7%.
- Free cash flow amounts to 177.9% of revenue for COYA, versus a peer median of 1371.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $125.6M | -17.2% | -9.0% | — | |
| LTM Mar 2026 | $98.81M | -44.1% | +10.1% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $97.99M | +60.1% | +25.1% | 1371.4% |
| LTM Mar 2026 | $71.69M | -1.0% | -2.9% | 45.6% | |
| LTM Mar 2026 | $41.95M | -15.4% | -12.2% | 589.1% | |
| LTM Mar 2026 | $41.28M | -26.9% | -27.8% | 4128.2% | |
| LTM Mar 2026 | $32.82M | +115.0% | +23.3% | — | |
| LTM Mar 2026 | $32.77M | +144.6% | +49.3% | — | |
| LTM Mar 2026 | $18.1M | -6.0% | -25.1% | 13509.0% | |
| LTM Mar 2026 | $14.12M | -7.5% | +14.0% | 177.9% | |
| LTM Mar 2026 | $8.74M | -16.5% | -27.6% | — | |
| Peer median (excluding COYA) | $41.62M | -10.7% | -6.0% | 1371.4% | |
Competitors are the stored peer set for COYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (4.89M) | (12.24M) | (7.99M) | (14.88M) | (21.23M) |
| Depreciation & Amortization | 16.13K | 27.36K | 27.36K | 27.36K | 27.36K |
| Deferred Income Tax | 399.68K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 233.22K | 207.35K | 872.25K | 2.66M | 4.29M |
| Change in Working Capital | 739.17K | 751.84K | (4.64M) | 1.88M | 3.88M |
| Accounts Receivables | 0 | 0 | (7.5M) | 7.5M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 665.17K | 845.28K | 298.82K | 477.45K | (527.01K) |
| Other Working Capital | 74K | (93.45K) | 2.56M | (6.1M) | 4.41M |
| Other Non-Cash Items | (399.68K) | 4.02M | 543.19K | 25K | 2.29M |
| Operating Cash Flow | (3.9M) | (7.24M) | (11.19M) | (10.29M) | (10.74M) |
| Capital Expenditures | (136.8K) | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (525K) | (543.19K) | (25K) | 0 |
| Investing Cash Flow | (136.8K) | (525K) | (543.19K) | (25K) | (1.16M) |
| Debt Repayment | 0 | 10.47M | 0 | 0 | 0 |
| Common Stock Issued | 1.32K | 158 | 38.34M | 14M | 20.35M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (341.9K) | (1.11M) | 89.95K | 2.02M | 0 |
| Financing Cash Flow | (340.58K) | 9.36M | 38.43M | 16.03M | 20.39M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (4.38M) | 1.59M | 26.69M | 5.71M | 8.48M |
| Free Cash Flow | (4.04M) | (7.24M) | (11.19M) | (10.29M) | (10.74M) |
Coya Therapeutics, Inc.
NASDAQ:COYA
Intrinsic Alpha fair value
Locked
Current Price
$3.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.